文献速递肿瘤 PET/CT

68Ga-THP-PSMA:一种可在室温下快速一步药盒法标记的前列腺癌PET显像剂

68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling.
PubMed 文献 · J Nucl Med · 2017-04-13

研究合成THP与脲基PSMA抑制剂的偶联物,通过直接向冷药盒中加入68Ga发生器洗脱液完成标记,5分钟内标记率>95%,产物在人血清中稳定超过6小时,对PSMA表达细胞有特异性结合。小鼠PET显像显示PSMA表达肿瘤特异性摄取达5.6±1.2%ID/cc(40-60分钟),除脾脏摄取降低外,肿瘤摄取、生物分布和药代动力学与68Ga-HBED-CC-PSMA无显著差异。

要点

  • 68Ga-THP-PSMA可在室温下5分钟内完成>95%标记,无需进一步操作。
  • 产物在人血清中稳定超过6小时,对PSMA表达细胞有特异性结合。
  • 小鼠PET显像肿瘤摄取5.6±1.2%ID/cc(40-60分钟),除脾脏外与68Ga-HBED-CC-PSMA无显著差异。

核心结论

  • 68Ga-THP-PSMA与其他68Ga-PSMA偶联物具有等效的显像特性,但标记过程大大简化。
  • THP为68Ga放射性药物的快速、简单、一步、室温注射器-药瓶法标记提供了前景。

研究设计与样本

  • 合成THP螯合剂与脲基PSMA抑制剂的偶联物,通过向含冷前体THP-PSMA和碳酸氢钠的药瓶中加入68Ga发生器洗脱液直接标记,无需进一步操作。
  • 标记后5分钟用快速薄层色谱和高效液相色谱分析。
  • 体外研究用PSMA表达的DU145-PSMA细胞及其不表达的对照DU145细胞测定PSMA亲和力。
  • 在荷相同细胞系异种移植瘤的小鼠中进行体内PET显像和离体生物分布研究,比较68Ga-THP-PSMA与68Ga-HBED-CC-PSMA。

主要发现

  • 室温下5分钟内标记完全(>95%),高效液相色谱显示单一放射性峰。
  • 产物在人血清中稳定超过6小时,对PSMA表达细胞有特异性结合,50%抑制浓度为361±60 nM。
  • 体内PET显像显示PSMA表达肿瘤特异性摄取,40-60分钟达5.6±1.2%ID/cc,血液清除快,向肾脏和膀胱聚集。
  • 除脾脏摄取降低外,肿瘤摄取、生物分布和药代动力学与68Ga-HBED-CC-PSMA无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical impact and accessibility of 68Ga tracers for the prostate-specific membrane antigen (PSMA) and other targets would be greatly enhanced by the availability of a simple, 1-step kit-based labeling process. Radiopharmacy staff are accustomed to such procedures in the daily preparation of 99mTc radiopharmaceuticals. Currently, chelating agents used in 68Ga radiopharmaceuticals do not meet this ideal. The aim of this study was to develop and evaluate preclinically a 68Ga radiotracer for imaging PSMA expression that could be radiolabeled simply by addition of 68Ga generator eluate to a cold kit. Methods: A conjugate of a tris(hydroxypyridinone) (THP) chelator with the established urea-based PSMA inhibitor was synthesized and radiolabeled with 68Ga by adding generator eluate directly to a vial containing the cold precursors THP-PSMA and sodium bicarbonate, with no further manipulation. It was analyzed after 5 min by instant thin-layer chromatography and high-performance liquid chromatography. The product was subjected to in vitro studies to determine PSMA affinity using PSMA-expressing DU145-PSMA cells, with their nonexpressing analog DU145 as a control. In vivo PET imaging and ex vivo biodistribution studies were performed in mice bearing xenografts of the same cell lines, comparing 68Ga-THP-PSMA with 68Ga-HBED-CC-PSMA. Results: Radiolabeling was complete (>95%) within 5 min at room temperature, showing a single radioactive species by high-performance liquid chromatography that was stable in human serum for more than 6 h and showed specific binding to PSMA-expressing cells (concentration giving 50% inhibition of 361 ± 60 nM). In vivo PET imaging showed specific uptake in PSMA-expressing tumors, reaching 5.6 ± 1.2 percentage injected dose per cubic centimeter at 40-60 min and rapid clearance from blood to kidney and bladder. The tumor uptake, biodistribution, and pharmacokinetics were not significantly different from those of 68Ga-HBED-CC-PSMA except for reduced uptake in the spleen. Conclusion:68Ga-THP-PSMA has equivalent imaging properties but greatly simplified radiolabeling compared with other 68Ga-PSMA conjugates. THP offers the prospect of rapid, simple, 1-step, room-temperature syringe-and-vial radiolabeling of 68Ga radiopharmaceuticals.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Young JD, Abbate V, Imberti C, et al. 68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling. J Nucl Med. 2017. PMID: 28408532. doi:10.2967/jnumed.117.191882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。